Featured Press Releases

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

BD Announces the First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

BD Announces the First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

  • 23 Jul 2025

BD (Becton, Dickinson and Company) a leading global medical technology company, announces the...

Zydus announces an exclusive licensing and supply agreement for two Gadolinium-based MRI injectable contrast agents in the U.S

Zydus announces an exclusive licensing and supply agreement for two Gadolinium-based MRI injectable contrast agents in the U.S

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

CorrectSequence Therapeutics

CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient: High-Precision Base Editing Clinical Treatment for Sickle Cell Disease

CorrectSequence Therapeutics

CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient: High-Precision Base Editing Clinical Treatment for Sickle Cell Disease

  • CorrectSequence Therapeutics
  • 27 Aug 2025
2025 Interim Results and Business Updates Announced by Innovent

2025 Interim Results and Business Updates Announced by Innovent

  • Innovent Biologics
  • 27 Aug 2025
Gvoke VialDx™ (glucagon injection) Launched by American Regent

Gvoke VialDx™ (glucagon injection) Launched by American Regent

  • American Regent, Inc
  • 27 Aug 2025
Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

  • Innovent Biologics
  • 25 Aug 2025
Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

  • Theravance Biopharma, Inc.
  • 25 Aug 2025
VASTHERA Receives U.S. FDA Clearance to Begin Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

VASTHERA Receives U.S. FDA Clearance to Begin Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

  • VASTHERA Co., Ltd.
  • 20 Aug 2025

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.